NCT05411094
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05411094
Title Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine California 92612 United States Details
Los Angeles General Medical Center Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868 United States Details
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 United States Details
University of Michigan - Brighton Center for Specialty Care Brighton Michigan 48116 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison Wisconsin 53718 United States Details
University of Wisconsin Carbone Cancer Center - University Hospital Madison Wisconsin 53792 United States Details
University Health Network-Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field